Onco360 Selected as the Preferred National Specialty Pharmacy Partner for XPOVIO® (selinexor)

Rhea-AI Summary

Onco360, the largest independent Oncology Pharmacy, partners with Karyopharm to distribute XPOVIO, a first-in-class XPO-1 inhibitor for multiple oncology indications. XPOVIO is approved for multiple myeloma and diffuse large B-cell lymphoma, addressing unmet medical needs. The partnership aims to improve access to XPOVIO for patients in need.

Insights

Oncology Pharmacist

The partnership between Onco360 and Karyopharm for the distribution of XPOVIO is a significant development in the field of oncology pharmaceuticals. XPOVIO, being a first-in-class XPO-1 inhibitor, represents a novel approach in treating multiple myeloma and diffuse large B-cell lymphoma (DLBCL). As an oncology pharmacist, it's crucial to understand the implications of this partnership for patient access to treatment. The availability of XPOVIO through Onco360 may improve the distribution efficiency and accessibility for patients, which is particularly important given the high relapse rate in multiple myeloma and the aggressive nature of DLBCL.

From a pharmaceutical standpoint, XPOVIO's mechanism of action, inhibiting the nuclear export protein XPO-1, offers a unique therapeutic option for patients who have exhausted other treatments. This could potentially lead to improved outcomes in a patient population with limited options. However, managing the complex treatment regimens and potential side effects will require specialized knowledge and patient education, which Onco360 is well-positioned to provide as a specialty pharmacy.

Market Research Analyst

The strategic partnership between Onco360 and Karyopharm could have a substantial impact on the market dynamics of oncology treatments. As a market research analyst, assessing the potential market penetration and growth prospects is essential. XPOVIO's approval for multiple indications broadens its target patient population, potentially increasing its market share in the oncology segment. Onco360's role as a national specialty pharmacy network partner may enhance Karyopharm's distribution capabilities and market reach, possibly leading to increased sales and revenue.

It is important to monitor how this partnership affects Karyopharm's market position relative to competitors, especially those with established treatments for multiple myeloma and DLBCL. The partnership's success will also depend on the efficacy and safety profile of XPOVIO, as well as the ability of Onco360 to effectively manage and support the treatment's distribution and patient adherence.

Financial Analyst

From a financial perspective, the partnership between Onco360 and Karyopharm is likely to influence Karyopharm's financial performance. As a financial analyst, it's important to evaluate how this partnership might affect Karyopharm's revenue streams, given that XPOVIO is approved for multiple oncology indications. The drug's positioning as a treatment option for patients with limited alternatives could command a premium pricing strategy, potentially leading to higher profit margins.

Investors should consider the costs associated with the partnership, such as marketing and distribution expenses, against the anticipated increase in sales volume. Additionally, the long-term financial impact will hinge on the drug's clinical success and adoption by healthcare providers. It's also vital to assess the potential risks, including competition from emerging therapies and the possibility of adverse clinical findings affecting drug utilization.

LOUISVILLE, Ky.--(BUSINESS WIRE)-- Onco360^®, the nation’s largest independent Oncology Pharmacy, is now the national specialty pharmacy network partner for Karyopharm’s product XPOVIO^® (selinexor), a first-in-class, XPO-1 inhibitor. XPOVIO is approved in multiple oncology indications, including: (i) in combination with Velcade® (bortezomib) and dexamethasone (XVd) in patients with multiple myeloma after at least one prior therapy; (ii) in combination with dexamethasone in patients with heavily pre-treated multiple myeloma; and (iii) in patients with diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy.

“Onco360 is excited to expand our partnership with the team at Karyopharm and become the preferred national specialty pharmacy partner for XPOVIO,” said Benito Fernandez, Chief Commercial Officer.

Multiple myeloma is an incurable hematological malignancy involving plasma cells. Only 50 percent of patients diagnosed with multiple myeloma survive past five years following initial diagnosis. The National Cancer Institute estimates that in 2018, approximately 30,770 new patients were diagnosed with multiple myeloma in the U.S.¹ Unfortunately, most multiple myeloma patients will relapse following the first complete remission and often require continuous treatment to prevent disease progression. Previously, there were no U.S. Food and Drug Administration (FDA)-approved products or regimens for patients with relapsed or refractory multiple myeloma who failed treatment with lenalidomide, pomalidomide, bortezomib, carfilzomib, and/or daratumumab.

XPOVIO is manufactured by Karyopharm Therapeutics, and has received multiple approvals from the U.S. FDA since 2019.² XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO-1.

Please see the full Prescribing Information for XPOVIO

About Onco360 Oncology Pharmacy:

Onco360 is the nation’s largest independent Oncology Pharmacy and clinical support services company. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, and ACHC-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit Onco360.com.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been an industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm's XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications and has received regulatory approvals in a growing number of ex-U.S. territories and countries, including Europe, the United Kingdom, China, South Korea, Israel, Singapore, Hong Kong, Mainland China, Australia, Canada, Taiwan and Macau, and is marketed in those areas by Karyopharm’s global partners. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in multiple myeloma, endometrial cancer and myelofibrosis. For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on Twitter at @Karyopharm and LinkedIn.

References:

1. National Cancer Institute, seer.cancer.gov. Key Statistics for Multiple Myeloma (2019).
2. https://www.clinicaltrials.gov/study/NCT02336815

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240313022739/en/

Benito Fernandez, Chief Commercial Officer

Benito.Fernandez@Onco360.com

516-640-1332

Source: Onco360 Oncology Pharmacy

FAQ

What is the partnership between Onco360 and Karyopharm regarding XPOVIO?

Onco360 is now the national specialty pharmacy network partner for Karyopharm's product XPOVIO, aimed at improving access to the medication for patients with multiple myeloma and diffuse large B-cell lymphoma.

What are the approved indications for XPOVIO?

XPOVIO is approved for multiple oncology indications, including in combination with Velcade and dexamethasone for multiple myeloma patients after prior therapy, heavily pre-treated multiple myeloma patients, and patients with diffuse large B-cell lymphoma.

How does XPOVIO function?

XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO-1, providing a unique mechanism of action for treating multiple myeloma and diffuse large B-cell lymphoma.

What is the significance of the partnership between Onco360 and Karyopharm for patients?

The partnership aims to improve access to XPOVIO, a crucial medication for patients with multiple myeloma and diffuse large B-cell lymphoma, addressing unmet medical needs in these patient populations.